Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Clinical Colorectal Cancer
|
June 22, 2019
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)
Rachel P Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, et al.
The Oncologist
|
September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
The Lancet. Gastroenterology & Hepatology
|
January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Philip A Philip, Jill Lacy, Fabienne Portales, et al.
The New England Journal of Medicine
|
May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
Stefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2024
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2025
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
Alberto Sobrero, Arvind Dasari, Jeneth Aquino, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
JAMA Oncology
|
October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Elisa Fontana, Jeff Meyers, Alberto Sobrero, et al.
Clinical Colorectal Cancer
|
June 22, 2019
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)
Rachel P Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, et al.
The Oncologist
|
September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
The Lancet. Gastroenterology & Hepatology
|
January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Philip A Philip, Jill Lacy, Fabienne Portales, et al.
The New England Journal of Medicine
|
May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2021
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
Stefano Cascinu, Rossana Berardi, Roberto Bianco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2024
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2025
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
Alberto Sobrero, Arvind Dasari, Jeneth Aquino, et al.
Page
of 8